Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Oral Dis ; 29(4): 1836-1844, 2023 May.
Article in English | MEDLINE | ID: mdl-35485180

ABSTRACT

OBJECTIVES: To assess halitosis parameters using OralChroma™ and the correlation with salivary flow, oral hygiene index, radiation dose, and tongue-coating index among irradiated head and neck cancer patients compared to patients without cancer. MATERIALS AND METHODS: This cross-sectional study enrolled irradiated and non-irradiated patients divided into two groups. Hydrogen sulfide, methyl mercaptan, and dimethyl sulfide (DMS) levels were measured using a gas chromatograph, and sialometry was performed. The tongue-coating index and simplified oral hygiene index were also assessed. RESULTS: Thirty-eight patients were allocated to each group. Volatile sulfur compound levels were above the thresholds in both groups. Non-irradiated individuals showed higher levels of hydrogen sulfide and dimethyl sulfide. Patients with asialia had an inexpressive tongue-coating index and increased dimethyl sulfide levels. A decrease in salivary flow rate was followed by a significant increase in volatile sulfur compound levels. Higher doses of radiation to the submandibular salivary glands were associated with higher concentrations of sulfide and methyl mercaptan. CONCLUSIONS: Head and neck radiotherapy may be important in the development of halitosis. Irradiated patients with asialia presented insignificant lingual biofilm. Consequently, lower levels of volatile sulfur compounds were detected in this group. Asialia, a severe radiation-induced hyposalivation, impacted the levels of DMS (extraoral origin).


Subject(s)
Halitosis , Hydrogen Sulfide , Xerostomia , Humans , Halitosis/etiology , Cross-Sectional Studies , Sulfur Compounds , Sulfhydryl Compounds , Xerostomia/etiology , Tongue
2.
Sao Paulo Med J ; 138(4): 326-335, 2020.
Article in English | MEDLINE | ID: mdl-32725058

ABSTRACT

BACKGROUND: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is still the most prevalent type of osteonecrosis with clinical relevance. In Brazil, bisphosphonate use is high but there is a lack of epidemiological studies on BRONJ. OBJECTIVE: To determine the clinical profile of BRONJ in a Brazilian population through an integrative review. DESIGN AND SETTING: Integrative review of BRONJ in a Brazilian population. METHODS: Cases and clinical research on Brazilians with BRONJ between 2010 and 2019, indexed in PubMed/MEDLINE, Scopus, Web of Science and LILACS were reviewed. Age, sex, type and time of bisphosphonate intake, administration route, related diseases, region of the BRONJ, diagnostic criteria, staging, triggering factor and type of treatment were analyzed. RESULTS: Fifteen articles on 128 subjects were included. Most patients were women (82.03%); the mean age was 63 years. Intravenous zoledronic acid was mostly used (62.50%), for breast cancer treatment (46.87%). The main localization of BRONJ was the mandible (54.68%), associated mainly with tooth extractions (45.98%). The diagnostic criteria were clinical (100%) and radiographic (89.06%), mostly in stage II (68.08%). The surgical treatments were sequestrectomy (37.50%) and platelet-rich plasma (PRP) (36.71%). Microbial control was done using chlorhexidine (93.75%) and infection control using clindamycin (53.90%). CONCLUSIONS: BRONJ had higher prevalence in Brazilian women receiving treatment for breast cancer and osteoporosis. The mandible was the region most affected with a moderate stage of BRONJ, particularly when there were histories of tooth extraction and peri-implant surgery. Sequestrectomy with additional drugs and surgical therapy was the treatment most accomplished.


Subject(s)
Bisphosphonate-Associated Osteonecrosis of the Jaw/surgery , Bone Density Conservation Agents/adverse effects , Diphosphonates/adverse effects , Tooth Extraction , Angiogenesis Inhibitors , Bisphosphonate-Associated Osteonecrosis of the Jaw/diagnostic imaging , Bisphosphonate-Associated Osteonecrosis of the Jaw/etiology , Bone Density Conservation Agents/administration & dosage , Brazil , Breast Neoplasms/drug therapy , Dental Care , Diphosphonates/administration & dosage , Female , Humans , Middle Aged , Osteoporosis/drug therapy , Treatment Outcome
3.
J Korean Assoc Oral Maxillofac Surg ; 46(2): 150-154, 2020 Apr 30.
Article in English | MEDLINE | ID: mdl-32364355

ABSTRACT

We present a case of osteoradionecrosis treated with leukocyte- and platelet-rich fibrin (LPRF) and surgery and followed up with clinical and tomographic investigations. A 65-year-old woman presented with pain in the posterior region of the right palate. Her medical history included cardiovascular disease and squamous cell carcinoma in the anterior region of the floor of the mouth that had been treated with intensity-modulated radiation therapy. Measurements of isodose curves showed a full dosage of 6,462.6 cGy in the anterior mandibular region, whereas that in the posterior region on the right side of the maxilla reached 5,708.1 cGy. Osteotomy was performed using rotary instruments, and debridement and placement of two LPRF membranes were also carried out. New gum tissue with no bone exposure was noted 14 days postoperatively. Tissue repair was complete, and the patient had no further complaints. During a 39-month follow-up period, the oral mucosa remained intact, and the patient was rehabilitated with a new upper denture. Since there is no consensus regarding the best protocol to treat osteoradionecrosis, LPRF might be an interesting adjuvant to a surgical approach. The use of LPRF is simple and reduces operational costs, time of handling, probability of technical failure, and associated morbidities for patients with osteoradionecrosis.

4.
Int J Implant Dent ; 5(1): 34, 2019 Oct 01.
Article in English | MEDLINE | ID: mdl-31571065

ABSTRACT

BACKGROUND: Medication-related osteonecrosis of the jaw (MRONJ) is characterized by the development of bone necrosis in the jaws of patients receiving antiresorptive and/or antiangiogenic medications. No scientific reports have been published yet on bevacizumab-related osteonecrosis of the jaw (BeRONJ) when associated with dental implant placement and adjuvant ozone therapy. CASE PRESENTATION: A 54-year-old female patient with a history of metastatic breast cancer and bevacizumab use presented with a dental infection. Dental extraction followed immediately by dental implant placement was planned after suspension of the bevacizumab treatment. The patient presented with pain, drainage of purulent secretion, and bone exposure 5 weeks post-surgery. Complete healing was achieved at postoperative 7 months. CONCLUSIONS: The combination of adjuvant ozone therapy and surgical debridement was effective for the treatment of MRONJ; however, the risk of MRONJ may persist after the suspension of bevacizumab for 28 days.

5.
J Oral Maxillofac Surg ; 76(1): 88-96, 2018 01.
Article in English | MEDLINE | ID: mdl-28675810

ABSTRACT

Lesions associated with medication-related osteonecrosis of the jaws (MRONJ) are refractory to different treatment approaches. Hence, auxiliary approaches capable of improving patient outcomes should be explored. Leukocyte- and platelet-rich fibrin (LPRF) is a second-generation platelet concentrate (natural autologous fibrin matrix). It shows anti-infectious activity through immune regulation and accelerates the angiogenesis and multiplication of fibroblasts and osteoblasts; in consequence, it stimulates soft tissue healing and prevents exposure of the alveolar bone in the oral cavity. This report describes 2 cases involving women with breast cancer who were being treated with zoledronic acid and exhibited advanced MRONJ. In case 1, MRONJ developed in the maxilla after dental extraction; in case 2, it was assumed that MRONJ arose spontaneously in the mandible because no other risk factors could be detected. These cases were managed with surgical resection of the necrotic bone followed by placement of an LPRF membrane. Complete wound healing and intact mucosal cover were achieved. At clinical and tomographic follow-up after 2 years, there were no oral lesions or complaints. Therefore, this could be a noninvasive, quick, and alternative approach to manage bone exposure. The LPRF membrane contributes to a successful outcome and acts as a physical barrier against micro-organisms, thus preventing secondary infections.


Subject(s)
Bisphosphonate-Associated Osteonecrosis of the Jaw/therapy , Bone Density Conservation Agents/adverse effects , Bone Neoplasms/drug therapy , Leukocytes , Platelet-Rich Fibrin , Zoledronic Acid/adverse effects , Aged , Anti-Bacterial Agents/therapeutic use , Bisphosphonate-Associated Osteonecrosis of the Jaw/diagnostic imaging , Bone Neoplasms/secondary , Breast Neoplasms/pathology , Combined Modality Therapy , Debridement , Female , Humans , Membranes, Artificial , Suture Techniques
6.
Asian Pac J Cancer Prev ; 17(3): 911-5, 2016.
Article in English | MEDLINE | ID: mdl-27039811

ABSTRACT

Leukemia is the most common neoplastic disease of the white blood cells which is important as a pediatric malignancy. Oral manifestations occur frequently in leukemic patients and may present as initial evidence of the disease or its relapse. The symptoms include gingival enlargement and bleeding, oral ulceration, petechia, mucosal pallor, noma, trismus and oral infections. Oral lesions arise in both acute and chronic forms of all types of leukemia. These oral manifestations either may be the result of direct infiltration of leukemic cells (primary) or secondary to underlying thrombocytopenia, neutropenia, or impaired granulocyte function. Despite the fact that leukemia has long been known to be associated with oral lesions, the available literature on this topic consists mostly of case reports, without data summarizing the main oral changes for each type of leukemia. Therefore, the present review aimed at describing oral manifestations of all leukemia types and their dental management. This might be useful in early diagnosis, improving patient outcomes.


Subject(s)
Leukemia/complications , Leukemia/pathology , Mouth Diseases/etiology , Mouth Diseases/pathology , Disease Management , Granulocytes/pathology , Humans , Neutropenia/etiology , Neutropenia/pathology , Thrombocytopenia/etiology , Thrombocytopenia/pathology
7.
Rev. bras. cancerol ; 55(2): 151-155, abr.-jun. 2009. ilus
Article in Portuguese | LILACS | ID: lil-534460

ABSTRACT

A osteonecrose dos maxilares induzida por bisfosfonatos é a primeira complicação tardia da terapia com bisfosfonatos descrita na literatura científica. Essa é definida como o desenvolvimento de osso necrótico na cavidade oral de um paciente que esteja recebendo tratamento com bisfosfonatos e não tenha recebido radioterapia em região de cabeça e pescoço. Clinicamente, as lesões se caracterizam como ulcerações da mucosa oral, frequentemente muito dolorosas, que expõem o osso subjacente. O objetivo deste trabalho é relatar um caso clínico de osteonecrose induzida por bisfosfonatos de surgimento espontâneo, com difícil resposta a tratamento conservador, alcançando a cura com cirurgia.


Subject(s)
Humans , Female , Aged , Diphosphonates/adverse effects , Diphosphonates/therapeutic use , Jaw , Osteonecrosis/surgery , Osteonecrosis/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...